AFFX Affymetrix, Inc.

Affymetrix Inc. (Nasdaq:AFFX) and Vanderbilt-Ingram Cancer Center announced today that they have entered into a three-year translational research collaboration to analyze genomic information across a large number of patient samples. Under terms of the agreement, researchers at Vanderbilt-Ingram and Vanderbilt University Medical Center will use Affymetrix GeneChip� microarray technology to develop new applications for translational research projects, focusing on disease areas such as cancer and HIV/AIDS. �Cancer is a genetic disease. The technological capabilities that Affymetrix provides in gene expression and genotyping provides an important set of tools to examine the molecular and genetic basis of cancer,� said Shawn Levy, Ph.D., assistant professor of biomedical informatics and director of the Vanderbilt Microarray Shared Resource. �This partnership provides a mechanism to bring these technologies to the forefront of translational research in helping Vanderbilt understand not only the molecular basis for the disease but also the genetic disparities in various cancers and responses to therapy.� The HIV/AIDS translational research project will aim to help clinicians avoid the often irreversible and costly complications of therapy. The Affymetrix Human Mitochondrial Resequencing Array 2.0 will be used as a research tool to identify genetic variants that may make some patients more susceptible to adverse effects of certain drugs. The results of this study will potentially help clinicians select the most appropriate drug therapy for each patient, avoiding those most likely to cause toxicity. Such a tool could have important applications for HIV/AIDS treatment in both affluent and resource-limited settings, and for other diseases. "A number of important translational projects are underway, ranging from cancer research to HIV/AIDS drug toxicities to age-related macular degeneration,� said Jeff Canter M.D., M.P.H., assistant professor of molecular physiology and biophysics at the Center for Human Genetics Research at Vanderbilt University Medical Center. �This is a very exciting time because new sequencing technologies allow us to explore real-world applications of discoveries from the revolution in genetics that until now have been confined to the laboratory.� �Vanderbilt University�s Vanderbilt-Ingram Cancer Center is one of the premier cancer research facilities in the United States,� said Fred Pollock, associate director of translational medicine at Affymetrix. �We are excited about moving forward with this translational medicine partnership that is designed to accelerate genetic research and bring better healthcare to patients.� Affymetrix collaborates with academic institutions, advocacy groups and the pharmaceutical and�diagnostics�community through its Translational�Medicine�Program to develop�molecular signatures for improving patient care. Affymetrix GeneChip microarray technology helps researchers diagnose and�tailor treatments for individual patients�by identifying and measuring the genetic information associated with complex diseases. The�Translational�Medicine�Program complements the Powered by Affymetrix� program, which enables companies to license GeneChip technology to create innovative, custom-designed microarray products based on signatures such as those of our Translational Medicine Program partners. This technology is already being used in many applications, including diagnostics, forensics, animal, industrial and food testing. About Vanderbilt-Ingram Cancer Center (VICC) The Vanderbilt-Ingram Cancer Center at Vanderbilt University Medical Center is dedicated to a comprehensive, interdisciplinary approach to cancer care, research, prevention and patient and community education. With nearly 300 investigators, Vanderbilt-Ingram is ranked among the top 10 centers in total research funding from the National Cancer Institute and generates more than $150 million each year in research support from public and private sources. Vanderbilt-Ingram is the only National Cancer Institute-designated Comprehensive Cancer Center in Tennessee and one of only 39 to achieve this distinction nationwide. The center is consistently recognized among the best places for cancer care by U.S. News & World Report. For more information, visit us online at www.vicc.org. About Affymetrix Affymetrix scientists invented the world�s first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip� technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world�s top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and nonprofit research institutes. More than 1,400 systems have been installed around the world and more than 7,000 peer-reviewed papers have been published using the technology. Affymetrix� patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., Bedford, Mass., and Singapore. The company maintains important sales and marketing operations in Europe and Asia and has about 1,100 employees worldwide. For more information about Affymetrix, please visit the company�s website at www.affymetrix.com. All statements in this press release that are not historical are �forward-looking statements� within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix� �expectations,� �beliefs,� �hopes,� �intentions,� �strategies� or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties associated with the agreement with Vanderbilt-Ingram Cancer Center discussed in this press release; risks of the company�s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties relating to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix� Form 10-K/A for the year ended December 31, 2005, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix� expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo and GeneChip are registered trademarks owned or used by Affymetrix Inc.